SkyView Investment Advisors’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.26M Sell
44,796
-956
-2% -$25.5K 0.17% 81
2025
Q4
$1.14M Sell
45,752
-800
-2% -$20.2K 0.14% 95
2025
Q3
$1.19M Buy
46,552
+3,655
+9% +$90.2K 0.15% 91
2025
Q2
$1.04M Buy
42,897
+2,770
+7% +$64.6K 0.15% 110
2025
Q1
$1.02M Buy
40,127
+12,220
+44% +$320K 0.15% 109
2024
Q4
$740K Buy
+27,907
New +$757K 0.12% 151
2023
Q4
Sell
-1,020
Closed -$34K 404
2023
Q3
$34K Sell
1,020
-11,973
-92% -$423K 0.01% 298
2023
Q2
$477K Sell
12,993
-3,901
-23% -$152K 0.12% 223
2023
Q1
$690K Sell
16,894
-332
-2% -$14.3K 0.16% 168
2022
Q4
$883K Sell
17,226
-2,649
-13% -$127K 0.27% 124
2022
Q3
$870K Buy
19,875
+1,758
+10% +$85.4K 0.25% 137
2022
Q2
$950K Buy
18,117
+5,605
+45% +$286K 0.25% 137
2022
Q1
$617K Sell
12,512
-36
-0.3% -$1.87K 0.15% 206
2021
Q4
$781K Sell
12,548
-5,426
-30% -$269K 0.18% 147
2021
Q3
$773K Buy
17,974
+6,934
+63% +$307K 0.22% 126
2021
Q2
$400K Hold
11,040
0.19% 114
2021
Q1
$400K Sell
11,040
-524
-5% -$18.6K 0.18% 121
2020
Q4
$426K Buy
+11,564
New +$424K 0.2% 102

Other funds holding PFE

SkyView Investment Advisors's PFE Position: Q1 2026 in Review

SkyView Investment Advisors reduced its Pfizer (PFE) stake by 2.1% in Q1 2026, selling an estimated $25.5K and leaving 44,796 shares worth $1.26M. The position accounts for 0.17% of the portfolio, ranked #81.

SkyView Investment Advisors first reported a position in PFE in Q4 2020 and has held it in 18 quarters since. 2,953 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • SkyView Investment Advisors held 44,796 shares of Pfizer worth $1.26M as of Q1 2026.
  • SkyView Investment Advisors sold 956 Pfizer shares in Q1 2026, an estimated $25.5K.
  • Pfizer made up 0.17% of SkyView Investment Advisors's portfolio in Q1 2026, its #81 holding.
  • SkyView Investment Advisors first reported a position in Pfizer in Q4 2020 and has held it in 18 quarters since.
  • 2,953 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on SkyView Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.